Masimo Corp (NASDAQ:MASI)

CAPS Rating: 4 out of 5

A global medical technology company that develops, manufactures and markets non-invasive patient monitoring products that improve patient care.

Results 1 - 20 of 25 : 1 2 Next »

Recs

0
Member Avatar SqwiiTrader (37.30) Submitted: 10/30/2013 5:45:00 PM : Underperform Start Price: $27.40 MASI Score: +8.77

TOS prediction

Recs

1
Member Avatar ROEoutshinesGOLD (98.58) Submitted: 4/2/2013 6:32:29 AM : Outperform Start Price: $19.75 MASI Score: +15.62

Business Summary:

Masimo Corporation was incorporated in California in May 1989 and reincorporated in Delaware in May 1996. On August 13, 2007, the Company completed its initial public offering.

It is a global medical technology company that develops, manufactures and markets noninvasive patient monitoring products that improve patient care. The Company develops, manufactures, and markets a family of noninvasive blood constituent patient monitoring solutions that consists of a monitor or circuit board and its proprietary single-patient use and reusable sensors and cables. In addition, it offers remote monitoring and clinician notification solutions, such as the Masimo Patient SafetyNet.

Its solutions and related products are based upon the proprietary Masimo SET algorithms. The Company invented Masimo Signal Extraction Technology, or Masimo SET, which provides the capabilities of Measure-Through Motion and Low Perfusion pulse oximetry to address the primary limitations of conventional pulse oximetry.

Pulse oximetry is the noninvasive measurement of the oxygen saturation level of arterial blood, or the blood that delivers oxygen to the body's tissues, and pulse rate.

The Company's Masimo SET platform has addressed many of the previous technology limitations and has been referred to by several industry sources as the gold standard in pulse oximetry. The benefits of Masimo SET have been validated in over 100 independent clinical and laboratory studies. This software-based technology is incorporated into a variety of product platforms depending on its customers' specifications.

The Company's Masimo SET MS circuit boards perform all signal processing and other pulse oximetry functions incorporating the Masimo SET platform. Its next-generation circuit board is the foundation for the Masimo Rainbow SET Pulse CO-Oximetry platform, utilizing technology licensed from Masimo Labs.

The MX circuit boards measure arterial blood oxygen saturation levels and pulse rate, and have the circuitry to enable the measurement of total hemoglobin, oxygen content, carboxyhemoglobin, methemoglobin, PVI, and acoustic respiration rate, along with other potential parameters in the future.

The Radical-7 incorporates the MX circuit board, which enables Rainbow SET parameters, and offers three-in-one capability to be used as:
- a standalone device for bedside monitoring;
- a detachable, battery-operated handheld unit for easy portable monitoring;
- and a monitor interface via SatShare, proprietary technology allowing its products to work with certain competitor products, to upgrade existing conventional multi-parameter patient monitors to Masimo SET while displaying Rainbow parameters on the Radical-7 itself.

The Rad-87, which also contains Masimo Rainbow SET technology, is a compact, lightweight and easy-to-use device designed specifically for use in less acute settings than the Radical-7.

The Rad-8 is a bedside pulse oximeter featuring Masimo SET with a low cost design and streamlined feature set, allowing it to be offered at a lower price point than the Radical-7 or Rad-87.

Rad-57 provides continuous, noninvasive measurement of carboxyhemoglobin and methemoglobin in addition to oxygen saturation, pulse rate, perfusion and index. Its rugged and lightweight design makes it applicable for use in hospital and field settings, specifically for fire departments and EMS units.

Patient SafetyNet is a remote monitoring and clinician notification system. It instantly routes bedside-generated alarms through a server to a qualified clinician's handheld paging device in real-time.

The Company sells its products to end-users through the direct sales force and certain distributors, and some of its products to the original equipment manufacturer, partners, for incorporation into their products.

The Company relies on a combination of patent, trademark, trade secret, copyright and other intellectual property rights and measures to protect its intellectual property.

Recs

0
Member Avatar subsurfacemapper (65.11) Submitted: 5/29/2012 12:43:40 AM : Outperform Start Price: $18.53 MASI Score: +3.54

Fool screen with ROE high, ltDepbt=zero, earnings up for 3 years 10%, etc.Market is around 1300 - I see support at 1200 although we are in downtrend and Europe is scary. It's a game - hope for the best.

Recs

0
Member Avatar Manifest (90.44) Submitted: 2/24/2012 8:33:28 AM : Outperform Start Price: $21.46 MASI Score: -12.23

We have Masimo (MASI) with a projected annual return of 14% and an excellent quality rating (82.9). My sisters are nurses and they say non-invasive stuff is good. Other colleagues expect Masimo products to extend beyond intensive care into General Hospital and even home for patient monitoring. Think telemetry, Star Trek ... and "Bones" McCoy.

For more: http://www.manifestinvesting.com/articles/201111stock

Recs

0
Member Avatar reeshau (53.02) Submitted: 12/22/2011 11:29:54 AM : Outperform Start Price: $17.43 MASI Score: +3.06

I think the selling is overdone here. I am worried that MASI is a one-trick pony, but I am encouraged by their efforts to exclude knockoffs from cutting off their sales of consumables. When your much larger competitor has to license your IP, you are doing well.

Recs

1
Member Avatar edjewett (< 20) Submitted: 10/26/2011 12:20:26 PM : Outperform Start Price: $18.61 MASI Score: -8.66

I interviewed at this company 2 years ago (didn't get the job :( ....) but having reasearched the business and seeing its future potential I really took a shine to it. As MASI is hitting a 52 wk low, I'm adding (doubling) my position in the company today. Although they missed the street's expectations (short term perspective) I am looking at the long term prospects for their growth and future opportunities overall and I think MASI is a long-term winner.

Recs

1
Member Avatar TMFRisingStars (32.31) Submitted: 9/13/2011 8:56:03 AM : Outperform Start Price: $21.76 MASI Score: -37.04

Here's the buy rec:
http://www.fool.com/investing/general/2011/09/12/this-may-be-the-next-great-growth-opportunity.aspx

Recs

1
Member Avatar TMFJMo (71.05) Submitted: 9/13/2011 8:47:15 AM : Outperform Start Price: $21.76 MASI Score: -37.04

Rising Star Buy:

http://www.fool.com/investing/general/2011/09/12/this-may-be-the-next-great-growth-opportunity.aspx

Recs

0
Member Avatar Covestor (26.78) Submitted: 3/11/2011 3:27:42 PM : Outperform Start Price: $29.50 MASI Score: -51.88

Covestor Model Manager Alphamark Advisors Bought MASI in his Small Cap Growth Covestor Model ( http://covestor.com/Alphamark-Advisors )

Recs

0
Member Avatar yooperking (74.75) Submitted: 11/1/2010 10:36:04 AM : Outperform Start Price: $28.45 MASI Score: -62.61

Matt Dolan, analyst, Roth Capital Partners says, "Cost-effectiveness is a good justification (for a hospital to buy this gear). The unquantifiable benefit comes from reducing patient risk." Masimo's noninvasive pulse oximetry systems are used in hospitals, out-patient surgery centers, by emergency services and will soon show up in physicians' offices.

Recs

0
Member Avatar Trimalerus (92.64) Submitted: 5/1/2010 3:17:17 AM : Outperform Start Price: $21.93 MASI Score: -34.86

My sister is type 1 Diabetic,so I know a bit about blood monitors. The Medical Industry has been hit hard by the economic downturn and increasing costs for patients. Companies such as Masimo will bounce back quickly in a recovery due to a high cost to benefit ratio of their products.

Recs

0
Member Avatar jge54515 (< 20) Submitted: 5/28/2009 5:14:46 PM : Outperform Start Price: $19.76 MASI Score: -71.47

non-invasive hgb monitoring is going to be hot

Recs

0
Member Avatar scrubs620 (< 20) Submitted: 5/15/2008 1:15:26 AM : Outperform Start Price: $30.32 MASI Score: -49.22

got FDA approval for a hemoglobin monitoring technology

Up on 6x normal volume

Recs

2
Member Avatar bravato (< 20) Submitted: 4/30/2008 2:20:52 PM : Outperform Start Price: $25.55 MASI Score: -33.75

Guys and gals, this is the kind of tip you're looking for:
My mother is the EMS coordinator for the Bay Area/Northern California fire and medical departments, and she is doing a revolutionary study on the long term effects of Carbon Monoxide on firefighter's respitory systems.
She has concluded, over a period of five plus years of intense research, that firefighters (especially forestry divisions) do not adequately protect against Carbon Monoxide, and the effects on the body are much worse than those from cigarettes.
Here's where MASIMO comes into play. . . She is working concurrently with Masimo, developing an on-site Carbon Monoxide monitoring device, to be used on firefighters on the scene of fires. If they show dangerous levels, they are to be put on Oxygen, which reverses the adverse effects of carbon monoxide.
She is working on a statewide/national bill that would REQUIRE ALL FIRE STATIONS TO USE THIS PRODUCT. Every single fire station in America will be using Masimo non invasive monitoring devices, thanks to my mother's hard work. . . you can thank us later :)

Recs

0
Member Avatar momlehane (< 20) Submitted: 3/24/2008 12:01:39 PM : Outperform Start Price: $23.90 MASI Score: -31.80

Massimo blood gas analyzers do something that the competition does not - it works with existing equipment AND it can function by itself as a new purchase. The strides that Masi has made in monitoring CO in the blood for Emergency Techs to use in the field has an incredible edge in initiating appropriate care in a timely manner.

Recs

0
Member Avatar Nathansstocks (< 20) Submitted: 1/1/2008 12:04:59 PM : Outperform Start Price: $34.22 MASI Score: -54.86

Right area, right time. With Boomers begining to retire this sector will outperform for the next several years...and this stock in particular is positioned for growth which will out pace the sector.

Recs

0
Member Avatar anthonysdaddy (42.33) Submitted: 12/7/2007 4:05:05 PM : Outperform Start Price: $33.18 MASI Score: -50.45

Masimo is the only manufacturer of a monitor that reads carboxi hemoglobin. That determines the levels of CO in your blood. That allows emergency medical providers to determine if you have CO poisoning without doing an arterial blood gas in the hospital. Speeding up treatment

Recs

0
Member Avatar eleyan (< 20) Submitted: 11/20/2007 11:54:45 AM : Outperform Start Price: $26.86 MASI Score: -35.85

They seem to have a very innovative solution in in measuring CO2 levels in the blood. I see in the news that some hospitals are already switching to their products. If it turns out to be a big hit and becomes a must have for every hospital then the stock will shoot up.

Recs

0
Member Avatar lessismore2007 (< 20) Submitted: 11/12/2007 3:57:28 PM : Outperform Start Price: $26.17 MASI Score: -32.15

As the largest demographic group in our country's history (baby boomers) grows older each day and begins to succumb to the ills of their fast food and high stress lifestyles, medical devices that improve patient care, are truly innovative, and developed by well run companies will do well. Very Well! The older we get, the more we fear death, the more we complain, the more we vote and demand Washington do something about our plight i.e. health care in the next 5-20 years.

Recs

0
Member Avatar mjoyce19 (< 20) Submitted: 11/10/2007 11:00:26 AM : Outperform Start Price: $25.89 MASI Score: -31.77

Its stock price continues to increase due to its gain in market share and prospects for the future. Also, there are talks about emerging technology that they have patented and are developing which can come to fruition within the next few years.

Results 1 - 20 of 25 : 1 2 Next »

Featured Broker Partners


Advertisement